Document:

Amendment to the Michigan License Agreement

 Exhibit 10.34 
 LICENSE AGREEMENT AMENDMENT 
 This is an Agreement, effective as of the 10th day of August, 1995 (the “Effective
Date”), between Matrigen, Inc., a corporation incorporated in the State of Delaware, with its principal place of business in the State of Michigan located at 425 North Main Street, Ann Arbor, MI 48104-4833 (“MATRIGEN”) , and the
Regents of the University of Michigan, a constitutional corporation of the State of Michigan (“MICHIGAN”), amending the License Agreement completed by these parties entitled “LICENSE AGREEMENT / MICHIGAN FILE NOS. 800, 800p1, 926,
926p1, 926p2, 926p3, 938, 1019 and 1116 TECHNOLOGY,” and effective as of July 13, 1995 (the “License Agreement”). MATRIGEN and MICHIGAN agree as follows: 
 Article XXIX, “Provisional Effective Period,” is hereby deleted from the License Agreement in its entirety. 
 IN WITNESS WHEREOF, the Parties hereto have executed this Agreement in duplicate originals by their duly authorized officers or representatives. 
  

									
	FOR MATRIGEN, INC.	 		 	FOR THE REGENTS OF THE UNIVERSITY OF MICHIGAN
					
	By	  	 /s/ Steven Goldstein
	 		 	By	 	 /s/ Robert L. Robb

		  	(authorized representative)	 		 		 	(authorized representative)
	Typed Name	  	Steven Goldstein	 		 	Typed Name	 	Robert L. Robb
	Title	  	President	 		 	Title	 	Director, Technology Management Officer
	Date	  	9-8-95	 		 	Date	 	9-8-95

 LICENSE AMENDMENT-MATRIGEN-9/6/95 
  

 1Second Amendment to the Michigan License Agreement

 Exhibit 10.35 
 SECOND AMENDMENT TO THE LICENSE AGREEMENT BETWEEN THE REGENTS OF THE UNIVERSITY OF MICHIGAN (“MICHIGAN”; File Nos. 800, 800P1, 926, 926P1, 926P2, 926P3, 938, 1019, AND 1116) and SELECTIVE GENETICS, INC. (“SELECTIVE”)

 This Amendment is to the Agreement between MICHIGAN and SELECTIVE (formerly Prizm Pharmaceuticals, Inc.; UM File Nos. 800, 800P1, 926, 926P1, 926P2,
926P3, 938, 1019, and 1116), which Agreement was effective July 13, 1995 between MICHIGAN and Matrigen, Inc. and which Agreement had been assigned by Matrigen, Inc. to Prizm Pharmaceuticals, Inc. in March of 1998. 
 On April 8, 2003, SELECTIVE notified MICHIGAN of its desire to remove its rights to UM File Nos. 800, 800P1, 926P2 and 1116 from the scope of the Agreement.

 Effective February 1, 2004, SELECTIVE, a corporation of the State of Delaware, with offices located at 11035 Roselle St, San Diego, CA 92121 and
MICHIGAN, a constitutional corporation of the State of Michigan, hereby amend their License Agreement of JULY 13, 1995 as follows: 
 1. The parties agree
that, to the extent MICHIGAN Files 1178 and 1178c1 have not already been added to the scope of Licensed Patents in Exhibit A to the License Agreement, these Files are hereby added to the scope of Exhibit A. SELECTIVE agrees to reimburse MICHIGAN for
past patent costs of $3,608 no later than March 1, 2004. 
 I. EXHIBIT A is amended to read as follows: 
 Exhibit A 
 TO THE LICENSE AGREEMENT FOR
MICHIGAN FILES 926, 926p1, 926p3, 926p3C1, 926p3C2, 1178 and 1178C1 
 AS AMENDED 1 FEBRUARY 2004 
 BETWEEN SELECTIVE GENETICS, INC. AND THE REGENTS OF THE UNIVERSITY OF MICHIGAN, 
 (ORIGINALLY EFFECTIVE 13 JULY 1995 
 BETWEEN MATRIGEN, INC., AND THE REGENTS OF THE
UNIVERSITY OF MICHIGAN FOR File Nos. 800, 800P1, 926, 926P1, 926P2, 926P3, 938, 1019, AND 1116) 
 PATENTS, PATENT APPLICATIONS, and MICHIGAN
FILES 
 File No. 0926 
  

	 	•	 	 US Patent No. 5,763,416 Issued 06/09/98 

 File
No. 0926p1 
  

	 	•	 	 AU Patent No. 698906 Issued 10/12/98 

	 	•	 	 US Patent No. 5,942,496 Issued 08/24/99 

  

	 	•	 	 JP Patent No. 3054634 Issued 04/14/00 

  

	 	•	 	 CA Application No. 2183542 

  

	 	•	 	 PCT Application No. PCT/US95/02251 

  

	 	•	 	 EP Patent No. 0741785I Issued 11/03/99 

  

	 	•	 	 AT Patent No. 0741785 Issued 11/03/99 and E186327 Issued 02/03/00 

  

	 	•	 	 BE Patent No. 0741785 Issued 11/03/99 

  

	 	•	 	 CH Patent No. 0741785 Issued 11/03/99 

  

	 	•	 	 DE Patent No. 69513149.4-08 Issued 11/03/99 

  

	 	•	 	 DK Patent No. 0741785 Issued 11/03/99 

  

	 	•	 	 ES Patent No. 0741785 Issued 11/03/99 and 2139889 Issued 12/23/99 

  

	 	•	 	 FR Patent No. 0741785 Issued 11/03/99 and AA22482 EP/FR Issued 02/02/00 

  

	 	•	 	 GB Patent No. 0741785 Issued 11/03/99 

  

	 	•	 	 IE Patent No. 0741785 Issued 11/03/99 

  

	 	•	 	 It Patent No. 0741785 Issued 11/03/99 and 67175BE/2000 Issued 01/19/00 

  

	 	•	 	 LU Patent No. 0741785 Issued 11/03/99 

  

	 	•	 	 MC Patent No. 0741785 Issued 11/03/99 

  

	 	•	 	 NL Patent No. 0741785 Issued 11/03/99 

  

	 	•	 	 SE Patent No. 0741785 Issued 11/03/99 and EP-SE-2000296 Issued 2/03/00 

 File No. 0926p3 
  

	 	•	 	 US Patent No. 5,962,427 Issued 10/05/99 

  

	 	•	 	 PCT Application No. PCT/US97/07301 

  

	 	•	 	 AU Patent No. 710386 Issued 01/20/00 

  

	 	•	 	 CA Application No. 2251655 

  

	 	•	 	 CN Application No. 97195326.0 

  

	 	•	 	 EP Application No. 97922578.6 

  

	 	•	 	 JP Application No. 09-537463 

  

	 	•	 	 KR Application No. 708098/98 

  

	 	•	 	 MX Application No. 988427 

  

	 	•	 	 NO Application No. P19984729 

  

	 	•	 	 PL Application No. P.343864 and PL19970343842 

  

	 	•	 	 RU Patent No. 2170104 Issued 07/10/01 

 File
No. 0926p3C1 
  

	 	•	 	 US Application No. 09/344,581 

 File
No. 0926p3C2 
  

	 	•	 	 US Application No. 10/177,680 

  

 2 

 File No. 1178 
  

	 	•	 	 US Application No. 10/177,680 

  

	 	•	 	 PCT Application No. PCT/US97/10079 

  

	 	•	 	 CA Application No. 2257976 

  

	 	•	 	 AU Patent No. 715339 Issued 05/11/2000 

  

	 	•	 	 JP Application No. 10-501785 

  

	 	•	 	 IL Application No. 127446 

  

	 	•	 	 EP Application No. 97929915.3 

  

	 	•	 	 US Patent No. 6,143,037 Issued 11/07/2000 

  

	 	•	 	 ILd1 Application No. 153374 

 File
No. 1178c1 
  

	 	•	 	 US Application No. 09/616,585 

 IN WITNESS
WHEREOF, the parties hereto have executed this Agreement in duplicate originals by their duly authorized officers or representatives. 
  

											
	FOR SELECTIVE GENETICS, INC.	 		 		  	FOR THE REGENTS OF THE UNIVERSITY OF MICHIGAN	  	
		  		 		 		  		  	
	By	  	 /s/ Barbara Sosnowski
	 		 	By	  	 /s/ Kenneth J. Nisbet
	  	
		  	(authorized representative)	 		 		  	(authorized representative)	  	
	Typed Name	  	Barbara Sosnowski	 		 	Typed Name	  	Kenneth J. Nisbet	  	
	Title	  	Vice President R&D	 		 	Title	  	Executive Director UM Technology Transfer	  	
	Date	  	2/10/04	 		 	Date	  	2/12/04	  	

  

 3Third Amendment to the Michigan License Agreement

 Exhibit 10.36 
 THIRD AMENDMENT TO LICENSE AGREEMENT 
 This Third Amendment to License Agreement (“Amendment”),
dated 10 August 2006 (“Amendment Date”), is by and among Tissue Repair Company (“LICENSEE”), the Regents of the University of Michigan (“MICHIGAN”) and Cardium Biologics, Inc. (“BUYER”). 
 WHEREAS, Matrigen, Inc. (“Matrigen”), and MICHIGAN entered into a license agreement dated 13 July 1995; which license agreement was
assigned by Matrigen, to Prizm Pharmaceuticals, Inc. (“Prizm”) in March of 1998; after which Prizm changed its name to Selective Genetics, Inc. (“Selective Genetics”); and after which LICENSEE accepted all the rights and
responsibilities of Selective Genetics under such license agreement as of 16 March 2005. 
 WHEREAS, the parties desire to modify
certain provisions of such license agreement (as amended 10 August 1995, and 1 February 2004, “License Agreement”) as provided herein. 
 WHEREAS, Matrigen and MICHIGAN entered into a roundtable research agreement dated 13 July 1995; which roundtable research agreement was assigned by Matrigen to Prizm Pharmaceuticals, Inc. (“Prizm”) in
March of 1998; after which Prizm changed its name to Selective Genetics, Inc. (“Selective Genetics”); after which such roundtable research agreement was amended in 12 February, 2004; after which LICENSEE accepted all the rights and
responsibilities of Selective Genetics under such roundtable research agreement as of 16 March 2005; and after which such roundtable research agreement was terminated effective as of June 30, 2005. 
 WHEREAS, Cardium Therapeutics, Inc., BUYER and LICENSEE are entering into an Asset Purchase Agreement (the “Asset Purchase Agreement”) pursuant
to which BUYER will purchase from LICENSEE substantially all of the assets, properties, rights and claims of LICENSEE’s business including the License Agreement, on the terms and conditions of the Asset Purchase Agreement. 
 WHEREAS, the parties desire to confirm that the License Agreement is separate from the previously-terminated roundtable research agreement and that the
License Agreement, as it is to be transferred to BUYER, is not intended to incorporate or impose upon BUYER any liabilities or obligations pursuant to the roundtable research agreement. 
 NOW THEREFORE, the parties hereby agree as follows: 
 1. Paragraph 2.3 shall be amended by deleting clause (b) in its entirety and replacing it with the following: 
 (b) was
conceived or made solely as defined by U.S. Patent law by one or more employees of MICHIGAN in the performance of the Roundtable Research Agreement effective as of the 1st day of July 1995 (as amended, restated or extended from time to time), by and
between MATRIGEN and MICHIGAN; 
  

 1 

 2. With regard to Paragraph 4.5 of the License Agreement (which related solely to the roundtable research
agreement), the License Agreement to be assumed by BUYER does not incorporate nor does it impose any liabilities or obligations with regard to the roundtable research agreement nor will the rights and interests of BUYER under this License Agreement
be in any way subject to reduction, forfeiture or default due to any matters associated with the roundtable research agreement. Accordingly, Paragraph 4.5 of the License Agreement is deleted in its entirety. 
 3. Paragraph 7.6 shall be deleted in its entirely and replaced with the following: 
 Notwithstanding Paragraph 7.2, LICENSEE has completed a Phase I study for the treatment of diabetic ulcers. A Phase II clinical study will be
initiated by February 10, 2008 (“MILESTONE I”). If such Phase II clinical study produces satisfactory positive data to proceed to a Phase III clinical study, a Phase III clinical study will by initiated within eighteen
(18) months following the completion of the unblinding of the data from such Phase II clinical study. If a Phase II clinical study is not initiated by February 10, 2008, the Parties shall negotiate in good faith a revised schedule under
which LICENSEE shall submit applications and obtain full government approval for Products. Failure to establish such a revised schedule by agreement of the Parties prior to May 10, 2008, and unless MICHIGAN otherwise agrees to further extend
such revised schedule (which shall not be unreasonably withheld or delayed), failure of LICENSEE to adhere to such revised schedule once established, shall give MICHIGAN the right to convert LICENSEE’s rights under this Agreement from exclusive
to non-exclusive and to terminate MICHIGAN’s covenant set forth in the second sentence of Paragraph 3.2. 
 4. Paragraph 8.3 shall
be deleted in its entirely and replaced with the following: 
 In the event of the termination of this Agreement, provided that a sublicensee
is not in breach of its obligations under this Agreement and upon written request of such sublicensee, MICHIGAN shall grant to such sublicensee a direct license under the Licensed Patents and Technology under terms and conditions no more onerous
than the terms and conditions of this Agreement. 
 5. MICHIGAN represents, acknowledges and agrees, as of the Amendment Date, as follows:

 (a) LICENSEE has succeeded to all right, title and interest of Matrigen, Prizm and Selective Genetics in and to the License Agreement, and
has taken all actions necessary with respect to LICENSEE to effectuate the same; 
 (b) The License Agreement is in full force and effect in
accordance with its terms and except as otherwise expressly set forth therein, has not been waived, modified, amended or restated; and 
 (c)
There has occurred no event that would constitute (including with the giving or notice, the passage of time or both) a default, breach or other event or occurrence that would give MICHIGAN the right to terminate, waive or otherwise reduce the rights
or interests of LICENSEE under the License Agreement. 
  

 2 

 6. Effective upon the closing of the transactions contemplated by the Asset Purchase Agreement,
(a) BUYER, as assignee of all right, title and interest in and to the License Agreement, accepts all of the terms and conditions of the License Agreement, and (b) MICHIGAN consents to the assignment and transfer by LICENSEE to BUYER of all
right, title and interest in and to the License Agreement, without further action by MICHIGAN. BUYER shall provide written notice to MICHIGAN of the assignment and transfer within 60 days of its occurrence. MICHIGAN represents, acknowledges and
agrees, after giving effect to such assignment and transfer, as follows: 
 (a) BUYER shall be the LICENSEE (as defined in the License
Agreement) as if it were the original signatory thereto; and 
 (b) Such assignment and transfer shall not constitute (including with the
giving or notice, the passage of time or both) a default, breach or other event or occurrence that would give MICHIGAN the right to terminate, waive or otherwise reduce the rights or interests of LICENSEE under the License Agreement. 
 7. Under certain circumstances set forth in the Asset Purchase Agreement, BUYER may reassign to LICENSEE all right, title and interest in and to the
License Agreement. Upon the effectiveness of such reassignment (if and only if it occurs), (a) LICENSEE accepts all of the terms and conditions of the License Agreement (and effectively becomes LICENSEE under the License Agreement as if the
License Agreement had not been assigned to BUYER), (b) MICHIGAN consents to such reassignment effective upon written notice to MICHIGAN thereof, but without further action by MICHIGAN, and (c) BUYER shall have no liabilities or obligations
owing to MICHIGAN in connection with the License Agreement arising or accruing at any time after the effective date of such reassignment. 
 8. Except as otherwise amended hereby, the License Agreement shall remain in full force in accordance with its terms. 
  

 3 

 IN WITNESS WHEREOF, the parties have duly executed and delivered this Amendment effective as of the
Amendment Date. 
  

			
	 TISSUE REPAIR COMPANY

		
	 By:
	 	 /s/ Barbara Sosnowski

	 Title:
	 	Pres & CEO
	
	 THE REGENTS OF THE UNIVERSITY OF MICHIGAN

		
	 By:
	 	 /s/ Ruth L. Rasor

	 Title:
	 	Director of Licensing
	
	 CARDIUM BIOLOGICS, INC.

		
	 By:
	 	 /s/ Tyler Dylan

	 Title:
	 	Chief Business Officer

  

 4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00119-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00119-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00119-of-00352.parquet"}]]